Table 4.

Number of patients reporting hypoglycaemic events during 24 weeks of treatment with nateglinide or gliclazide in combination with metformin

	Nateglinide + metformin n = 130	Gliclazide + metformin n = 126
Patients with at least one event suggestive of hypoglycaemia, n (%)	32 (24.6)	32 (25.4)
Patients with at least one confirmed event of hypoglycaemia, n (%)	28 (21.5)	28 (22.2)
Patients with ≥ 3 events suggestive of hypoglycaemia, n (%)	13 (10.0)	17 (13.5)
Patients with ≥ 3 events confirmed as hypoglycaemia, n (%)	12 (9.2)	16 (12.7)